Diagnostic and imaging considerations: Role of viability

Heart Failure Reviews

Volumn 11, Issue 2, 2006, Pages 125-134

  Senior, Roxy ^a  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

Diagnosis; Heart failure; Medical therapy; Myocardial; Revascularisation; Viability

Indexed keywords

ACETIC ACID C 11; DOBUTAMINE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; HEPTADECANOIC ACID; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NITRATE; PALMITIC ACID C 11; TETROFOSMIN TC 99M; THALLIUM 201;

CLINICAL TRIAL; CONTRAST ECHOCARDIOGRAPHY; CONTRAST ENHANCEMENT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEVELOPED COUNTRY; DIAGNOSTIC ACCURACY; DRUG HALF LIFE; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE REVASCULARIZATION; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; MORTALITY; MYOCARDIAL HIBERNATION; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STUNNED HEART MUSCLE; SURVIVAL RATE; SYMPTOM; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY, STRESS; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIAL REVASCULARIZATION; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33747876020     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-006-9483-y     Document Type: Review

References (94)

1. Bax JJ, van der Wall EE, Harbinson M. Radionuclide techniques for the assessment of myocardial viability and hibernation. Heart 2004;90(Supple 5):v26-33.
2. Melo LG, Pachori AS, Kong D, et al. Molecular and cell-based therapies for protection, rescue, and repair of ischemic myocardium: Reasons for cautious optimism. Circulation 2004;109:2386-93.
3. Cleland JGF, Pennell DJ, Ray SG, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS) trial. Lancet 2003;362:14-21.
4. Senior R, Lahiri A, Kaul S. Effect of revascularisation on left ventricular remodelling in patients with heart failure from severe chronic ischemic left ventricular dysfunction. Am J Cardiol 2001;88:624-8.
5. Rahimtoola SH. The hibernating myocardium. Am Heart J 1989;117:211-221.
6. Dispersyn GD, Borgers M, Flameng W. Apoptosis in chronic hibernating myocardium: Sleeping to death? Cardiovasc Res 2000;45:696-703.
7. Bax JJ, Visser FC, Poldermans D, et al. Time course of functional recovery of stunned and hibernating segments after surgical revasculaisation. Circulation 2001;104(Suppl 1):1314-8.
8. Beanlands RS, Hendry PJ, Masters RG, deKemp RA, Woodend K, Ruddy TD. Delay in revascularisation is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging. Circulation 1998;98(Suppl):151-6.
9. Canty JM, Suzuki G, Banas MD, Verheyen F, Borgers M, Fallavolita JA. Hibernating myocardium chronically adapted to ischemia but vulnerable to sudden death. Circ Res 2004;94:1142-1149.
10. Kim SJ, Depre C, Vatner SF. Novel mechanisms mediating stunned myocardium. Heart Failure Rev 2003;8:143-53.
11. Senior R, Lahiri A. Dobutamine echocardiography predicts functional outcome after revascularisation in patients with dysfunctional myocardium irrespective of the perfusion pattern of resting thallium-201 imaging. Heart 1999;82:668-73.
12. Alderman E, Fisher LD, Litwin P, et al. Results of coronary artery surgery in patients with poor left ventricular dysfunction (CASS). Circulation 1983;68:785-95.
13. Bounous EP, Mark DB, Pollock BG, et al. Surgical survival benefits for coronary disease patients with left ventricular dysfunction. Circulation 1988;78:1151-7.
14. Krishnamani R, El-Zaru M, DeNofrio D. Contemporary medical, surgical, and device therapies for end-stage heart failure. Curr Treat Options Cardiovasc Med 2003;5:487-99.
15. Baker DW, Jones R, Hodges J, Massie BM, Konstam MA, Rose EA. Management of heart failure. III. The role of revascularisation in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA 1994;272:1528-34.
16. Holmes DR Jr, Detre KM, Williams DO, et al. Long-term outcome of patients with depressed left ventricular function undergoing percutaneous transluminal coronary angioplasty; the NHLBI PTCA registration. Circulation 1993;87:21-9.
17. Marshall RC, Tillisch JH, Phelps ME, et al. Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography, 18-F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation 1983;67:766-88.
18. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron emission tomography. N Engl J Med 1986;314:884-8.
19. Knuuti MJ, Yki-Järvinen H, Voipio-Pulkki L-M, et al. Enhancement of myocardial 18-FDG uptake by nicotinic acid derivative. J Nucl Med 1994;35:989-98.
20. Bax JJ, Veening MA, Visser FC, et al. Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging: A comparative study using different protocols. Eur J Nucl Med 1997;24:35-41.
21. Knuuti MJ, Nuutila P, Ruotsalainen U, et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med 1992;33:1255-1262.
22. Tarakji KG, Brunken R, McCathy PM, Al-Chekakie MO, Abdel-Latif A, Pothier CE, et al. Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction. Circulation 2006;113:230-237.
23. Mäki MT, Haaparanta M, Luotolahti M, et al. Fatty acid uptake is preserved in chronically dysfunctional but viable myocardium. Am J Physiol 1997; 273 [Heart Circ Physiol 42: H2473-H2480].
24. Schulz G, von Dahl J, Kaiser HJ, et al. Imaging of β-oxidation by static PET with 14(R,S)-[18F]-fluoro-6-thiaheptadecanoic acid (FTHA) in patients with advanced coronary heart disease: A comparison with 18FDG-PET and 99mTc-MIBI SPET. Nucl Med Commun 1996;17:1057-64.
25. Wolpers HG, Burchert W, van den Hoff J, et al. Assessment of myocardial viability by use of 11C-acetate and positron emission tomography. Threshold criteria of reversible dysfunction. Circulation 1997;18(95):1417-1424.
26. Mori T, Minamiji K, Kurogane H, et al. Rest injected thallium-201 imaging for assessing viability of severe asynergic regions. J Nucl Med 1991;32:1718-24.
27. Ragosta M, Beller GA, Watson DD, et al. Quantitative planar rest-redistribution Tl-201 imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 1993;87:1630-1641.
28. Ohtani H, Tamaki N, Yonekura Y, et al. Value of thallium-201 reinjection after delayed SPECT imaging for predicting reversible ischemia after coronary artery bypass grafting. Am J Cardiol 1990;66:394-99.
29. Pohost GM, Alpert NS, Ingwall JS, et al. Thallium redistribution: mechanisms and clinical utility. Semin Nucl Med 1980;20:70-93.
30. Kayden DS, Sigal S, Sonfer R, et al. Thallium-201 for assessment of myocardial viability: Quantitative comparison of 24 hour redistribution imaging with reinjection at rest. J Am Coll Cardiol 1991;18:1480-6.
31. Dilsizian V, Rocco TP, Freedman NMT, et al. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990;66:394-99.
32. Hegewald MG, Palac RT, Angello DA, et al. Ribose infusion accelerates thallium redistribution with early imaging compared with late 24-hour imaging without ribose. J Am Coll Cardiol 1991;18:1671-81.
33. He ZX, Darcourt J, Guignier A, et al. Nitrates improve detection of ischaemic but viable myocardium by thallium-201 reinjection SPECT. J Nucl Med 1993;34:1472-77.
34. Bonow RO. The hibernating myocardium: Implications for management of congestive heart failure. Am J Cardiol 1995;75:17A-25A.
35. Bonow RO. Identification of viable myocardium. Circulation 1996;94:2674-80.
36. Senior R, Glenville B, Basu S, Sridhara BS, Anagnostou E, Stanbridge R, Edmondson SJ, Handler CE, Rafftery EB, Lahiri A. Dobutamine echocardiography and thallium-201 imaging predict functional improvement after revascularisation in severe ischaemic left ventricular dysfunction. Br heart J 1995;74:358-64.
37. Senior R, Raval U, Lahiri A. Tc-99m-labeled sestamibi imaging reliably identifies retained contractile reserve in dysynergic segments. J Nucl Cardiol 1995;2:296-302
38. Sciagra R, Bisi G, Santoro GM, et al. Influence of the assessment of defect severity and intravenous nitrate administration during tracer injection on the detection of viable hibernating myocardium with data-based quantitative technetium 99m-labelled sestamibi single photon emission computed tomography. J Nucl Cardiol 1996;3:221-230.
39. Schulz R, Guth BD, Peiper K, et al. Recruitment of an inotropic reserve in moderately ischaemic myocardium at the expense of metabolic recovery; a model of short term hibernation. Circ Res 1992;70:1282-95.
40. Chen C, Chen L, Fallon JT, et al. Functional and structural alterations with 24-hour myocardial hibernation and recovery after perfusion: A pig model of myocardial hibernation. Circulation 1996;94:3146-54.
41. Senior R, Lahiri A. Dobutamine echocardiography predicts functional outcome after revascularisation in patients with dysfunctional myocardium irrespective of the perfusion pattern on resting thallium-201 imaging. Heart 199;82:668-73.
42. Sun KT, Czernin J, Krivokapich J, et al. Effects of dobutamine stimulation on myocardial blood flow, glucose metabolism, and wall motion in normal and dysfunctional myocardium. Circulation 1996;94:314-54.
43. Krivokapich J, Czernin J, Schelbert HR. Dobutamine positron emission tomography: Absolute quantitation of rest and dobutamine myocardial blood flow and correlation with cardiac work and percent diameter stenosis in patients with and without coronary artery disease. J Am Coll Cardiol 1996;28:565-72.
44. Senior R, Lahiri A. Role of dobutamine echocardiography in detection of myocardial vaiability for predicting outcome after revascularisation in ischemic cardiomyopathy. J Am Soc Echocardiogr 2001;14:240-8.
45. Senior R, Lahiri A. Enhanced detection of myocardial ischaemia by stress dobutamine echocardiography utilising the "biphasic" response of wall thickening during low and high dose dobutamine infusion. J Am Coll Cardiol 1995;26:26-32.
46. Alfridi I, Kleimen NS, Raizner AE, Zoghbi WA. Dobutamine echocardiography in myocardial hibernation: Optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. Circulation 1995;91:663-670.
47. Rizzello V, Poldermans D, Schinkel AFL, Biagini E, Boersma E, Elhendy A, et al. Long term prognostic value of myocardial viability and ischaemia during dobutamine stress echocardiography in patients with ischaemic cardiomyopathy undergoing coronary revascularization. Heart 2006;92:239-44.
48. Hanekom L, Jenkins C, Jeffries L, Case C, Mundy J, Hawley C, Marwick TH. Incremental value of strain rate analysis as an adjunct to wall-motion scoring for assessment of myocardial viability by dobutamine echocardiography. Circulation 2006;112;3892-900.
49. Meltzer RS, Tickner EC, Popp RL. Why do the lungs clear ultrasonic contrast? Ultrasound Med Biol 1980;6:263-9.
50. Grayburn PA. Current and future contrast agents. Echocardiography 2002;19:259-65.
51. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998;97:473-83.
52. Swinburn JM, Lahiri S. Senior R. Intravenous myocardial contrast echocardiography predicts recovery of dysynergic-myocardium early after acute myocardial infarction. J Am Coll Cardiol 2001;38:19-25.
53. Jeetley P, Swinburn J, Hickman M, Bellenger NG, Pennell DJ, Senior R. Myocardial contrast echocardiography predicts left ventricular remodelling after acute myocardial infarction. J Am Soc Echocardiogr 2004;17:1030-6.
54. Brochet E, Caitrom D, Karila-Cohen D, Seknadji P, Faraggi M, Benamer H, et al. Early changes in myocardial perfusion patterns after myocardial infarction: Relation with contractile reserve and functional recovery. J Am Coll Cardiol 1998;52:2011-7.
55. Main ML, Magalski A, Chen NK, Coen MM, Skulnich DG, Good TH. Full-motion pulse inversion power Doppler contrast echocardiography differentiates stunning from necrosis and predicts recovery of left ventricular function after acute myocardial infarction. J Am Coll Cardiol 2001;38:1390-4.
56. Janardhanan R, Swinburn JM, Greaves K, Senior R. Usefulness of myocardial contrast echocardiography using low-power continuous imaging early after acute myocardial infarction to predict late functional left ventricular recovery. Am J Cardiol 2003;92:493-7.
57. deFilippi CR, Willett DL, Irani WN, Eichhorn EJ, Velasco CE, Grayburn PA. Comparison of myocardial contrast echocardiography and low-does-dobutamine stress echocardiography in predicting recovery of left ventricular function after coronary revascularisation in chronic ischaemic heart disease. Circulation 1995;92:2863-68.
58. Nagueh SF, Vaduganathan P, Ali N, Blaustein A, Verani MS, Winters WL Jr, et al. Identification of hibernating myocardium comparative accuracy of myocardial contrast echocardiography, rest-redistrihution thallium-201 tomography and dobutamine echocardiography. J Am Coll Cardiol 1997;29:985-993.
59. Shimoni R, Frangogiannis NG, Aggeli CJ, Shan K, Quinones MA, Espada R, et al. Microvascular structural correlates of myocardial contrast echocardiography in patients with coronary artery disease and left ventricular dysfunction: Implications for the assessment of myocardial hibernation. Circulation 2002;106:950-6.
60. Semelka RC, Tomei E, Wagner S, et al. Interstudy reproducibility of dimensional and functional measurements between cine magnetic resonance studies in the morphologically abnormal left ventricle. Am Heart J 1990;119:1367-73.
61. Shapiro EP, Rogers WJ, Beyar R, et al. Determination of left ventricular mass by magnetic resonance imaging in hearts deformed by acute infarction. Circulation 1989;79:706-11.
62. Holman ER, Buller VGM, de Roos A, et al. Detection and quantification of dysfunctional myocardium by magnetic resonance imaging. A new three-dimensional method for quantitative wall-thickening analysis. Circulation 1997;95:924-31.
63. Yang PC, Kerr AB, Liu AC, et al. New real-time interactive cardiac magnetic resonance imaging system complements echocardiography. J Am Coll Cardiol 1998;32:2056-94.
64. Mallory GK, White PD, Salcedo-Galger J. The speed of healing of myocardial infarction: A study of the pathologic anatomy in 72 cases. Am Heart J 1939;18:647-71.
65. Baer FM, Voth E, Schneider CA, et al. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [F18]fluorodeoxyglucose in patients with chronic coronary artery disease: A functional and morphological approach to the detection of residual myocardial viability. Circulation 1995;91:1006-15.
66. Baer FM, Theissen P, Schneider CA, et al. Dobutamine magnetic resonance imaging predicts recovery of chronically dysfunctional myocardium after successful revascularization. J Am Coll Cardiol 1998;31:1040-48.
67. Baer FM, Theissen P, Crnac J, et al. Head to head comparison of dobutamine-transoesophageal echocardiography and dobutamine-magnetic resonance imaging for the prediction of left ventricular functional recovery in patients with chronic coronary artery disease. Eur Heart J 2000;21:981-91.
68. Forder JR, Pohost GM. Cardiovascular nuclear magnetic resonance: Basic and clinical applications. J Clin Invest 2003;111:1630-39.
69. Rehwald WG, Fieno Ds, Chen EL, Kim RJ, Judd RM. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation 2002;105:224-9.
70. de Roos A, van Rossum AC, van der Wall E, et al. Reperfused and nonreperfused myocardial infarction: Diagnostic potential of Gd-DTPA-enhanced MR imaging. Radiology 1989;72:717-20.
71. Judd RM, Lugo-Olivieri CH, Arai M, et al. Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts. Circulation 1995;92:1902-10.
72. Lima JA, Judd RM, Bazille A, et al. Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms. Circulation 1995;92:1117-25.
73. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JA. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97:765-72.
74. Lardo AC, Cordeizo MAS, Silva C, Amado LC, George RT, Saliaris AP, et al. Contrast - enhanced multidetector computed tomography viability imaging after myocardial infarction. Circulation 2006;394-404.
75. Bax JJ, Poldermans D, Elhendy A, et al. Sensitivity, specificity and predictive accuracies of various non-invasive techniques for detecting hibernating myocardium. Curr Probl Cardiol 2001;26:141-88.
76. Bax JJ, Poldermans D, Elhendy A, et al. Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularisation in patients with chronic artery disease and viable myocardium detected by dobutamine stress echocardiography. J Am Coll Cardiol 1999;34:163-9.
77. Eitzman D, Al-Aouar ZR, Kanter HL, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992;20:559-65.
78. Di Carli MF, Davidson M, Little R, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994;73:527-33.
79. Marwick TH, Nemec JJ, Lafont A, et al. Prediction by postexercise fluoro-18 deoxyglucose positron emission tomography of improvement in exercise capacity after revascularization. Am J Cardiol 1992;69:854-59.
80. Di Carli MF, Asgarzadie F, Schelbert HR, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995;92:3436-44.
81. Yoshida K, Gould KI. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularisation. J Am Coll Cardio 1993;22:984-97.
82. Tamaki N, Kawamoto M, Takahashi N, et al. Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction: Comparison with stress thallium imaging. J Am Coll Cardiol 1993;22:1621-27.
83. Pagley PR, Beller GA, Watson DD, et al. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation 1997;96:793-800.
84. Cuocolo A, Petretta M, Nicolai E, et al. Successful coronary revascularization improves prognosis in patients with previous myocardial infarction and evidence of viable myocardium at thallium-201 imaging. Eur J Nucl Med 1998;25:60-8.
85. Zafrir N, Leppo JA, Reinhardt CP, et al. Thallium reinjection versus standard stress/delay redistribution imaging for prediction of cardiac events. J Am Coll Cardiol 1998;31:1280-85.
86. Pasquet A, Robert A, D'Hondt AM, Dion R, Melin JA, Vanoverschelde JL. Prognostic value of myocardial ischemia and viability in patients with chronic left ventricular ischemic dysfunction. Circulation 1999;100:141-8.
87. Meluzin J, Cerny J, Frelich M, et al. Prognostic value of the amount of dysfunctional but viable myocardium in revascularized patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 1998;32:912-20.
88. Afridi I, Grayburn PA, Panza J, et al. Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction. J Am Coll Cardiol 1998;32:921-26.
89. Chaudhry FA, Tauke JT, Alessandrini RS, et al. Prognostic implications of myocardial contractile reserve in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 1999;34:730-38.
90. Senior R, Kaul S, Lahiri A. Myocardial viability on echocardiography predicts long-term survival after revascularisation in patients with ischemic congestive heart failure. J Am Coll Cardiol 1999;33:1848-54.
91. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularisation on prognosis in patients with coronary artery disease and left ventricular systolic dysfunction: A metal-analysis. J Am Coll Cardiol 2002;109:2172-4.
92. Bourque JM, Hasselblad V, Velazquez EJ, Bourges-Neto MS, O'Connor CM. Revascularisation in patients with coronary artery disease, left ventricular dysfunction, and viability: A meta-analysis. Am Heart J 2003;146:621-7.
93. Cleland JG, Freemantle N, Ball SG, et al. The Heart Failure Revascularisation Trial (HEART) rationale, design and methodology. Eur J Heart Fail 2003;5:295-303.
94. Jones RH. Personal communication. Surgical treatment for ischemic heart failure (STICH). Available from: http://www.clinicaltrials.gov/ct/gui/ show/NCT00023595